- Home
- APLM vs BREA Comparison
APLM vs BREA Comparison
Compare APLM & BREA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- BREA
- Stock Information
- Founded
- APLM 2016
- BREA 2022
- Country
- APLM United States
- BREA Ireland
- Employees
- APLM N/A
- BREA N/A
- Industry
- APLM Blank Checks
- BREA Services-Misc. Amusement & Recreation
- Sector
- APLM Finance
- BREA Consumer Discretionary
- Exchange
- APLM Nasdaq
- BREA Nasdaq
- Market Cap
- APLM 7.7M
- BREA 8.7M
- IPO Year
- APLM N/A
- BREA 2023
- Fundamental
- Price
- APLM $6.71
- BREA $0.67
- Analyst Decision
- APLM Strong Buy
- BREA
- Analyst Count
- APLM 2
- BREA 0
- Target Price
- APLM $425.00
- BREA N/A
- AVG Volume (30 Days)
- APLM 42.6K
- BREA 255.7K
- Earning Date
- APLM 04-15-2025
- BREA 01-03-2025
- Dividend Yield
- APLM N/A
- BREA N/A
- EPS Growth
- APLM N/A
- BREA N/A
- EPS
- APLM N/A
- BREA N/A
- Revenue
- APLM $2,101,000.00
- BREA $2,872,101.00
- Revenue This Year
- APLM N/A
- BREA N/A
- Revenue Next Year
- APLM N/A
- BREA N/A
- P/E Ratio
- APLM N/A
- BREA N/A
- Revenue Growth
- APLM 70.54
- BREA 2338.69
- 52 Week Low
- APLM $6.20
- BREA $0.50
- 52 Week High
- APLM $63.00
- BREA $1.95
- Technical
- Relative Strength Index (RSI)
- APLM 43.33
- BREA 48.80
- Support Level
- APLM $6.20
- BREA $0.65
- Resistance Level
- APLM $8.00
- BREA $0.76
- Average True Range (ATR)
- APLM 1.37
- BREA 0.06
- MACD
- APLM -0.18
- BREA -0.00
- Stochastic Oscillator
- APLM 9.44
- BREA 37.96
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About BREA Brera Holdings PLC
Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.